Glioblastoma
IDH-wildtype disease that almost always recurs: EGFR, the blood-brain barrier and cell therapy attempts.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 36 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for glioblastoma on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 23 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | Clinical | genetic literature | Literature | Animal models | RNA expr. | Pathways |
|---|---|---|---|---|---|---|---|---|---|
| TP53Peds RMTL tumor protein p53 | 0.73 | 0.69 | 0.82 | ||||||
| EGFRPeds RMTL epidermal growth factor receptor | 0.69 | 0.38 | 0.80 | ||||||
| IDH1Peds RMTL isocitrate dehydrogenase (NADP(+)) 1 | 0.68 | – | 0.79 | ||||||
| PTENPeds RMTL phosphatase and tensin homolog | 0.64 | – | 0.83 | ||||||
| BRAFPeds RMTL B-Raf proto-oncogene, serine/threonine kinase | 0.63 | – | 0.77 | ||||||
| ATRXPeds RMTL ATRX chromatin remodeler | 0.63 | 0.18 | 0.80 | ||||||
| RB1 RB transcriptional corepressor 1 | 0.62 | – | 0.79 | ||||||
| NF1 neurofibromin 1 | 0.61 | – | 0.79 | ||||||
| TERTPeds RMTL telomerase reverse transcriptase | 0.59 | 0.80 | 0.53 | ||||||
| PIK3CAPeds RMTL phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.59 | – | 0.74 | ||||||
| FGFR1 fibroblast growth factor receptor 1 | 0.59 | – | 0.49 | ||||||
| PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 | 0.58 | 0.52 | 0.70 | ||||||
| GSR glutathione-disulfide reductase | 0.56 | – | – | ||||||
| PDGFRAPeds RMTL platelet derived growth factor receptor alpha | 0.55 | – | 0.64 | ||||||
| VEGFA vascular endothelial growth factor A | 0.55 | – | – | ||||||
| CDKN2A cyclin dependent kinase inhibitor 2A | 0.53 | 0.15 | 0.68 | ||||||
| PTPN11Peds RMTL protein tyrosine phosphatase non-receptor type 11 | 0.51 | – | 0.66 | ||||||
| H3-3A H3.3 histone A | 0.49 | – | 0.64 | ||||||
| CDKN2B cyclin dependent kinase inhibitor 2B | 0.49 | 0.77 | – | ||||||
| STAG2 STAG2 cohesin complex component | 0.47 | – | 0.61 | ||||||
| KITPeds RMTL KIT proto-oncogene, receptor tyrosine kinase | 0.47 | – | 0.57 | ||||||
| CDKN2C cyclin dependent kinase inhibitor 2C | 0.46 | – | 0.72 | ||||||
| PDGFRBPeds RMTL platelet derived growth factor receptor beta | 0.45 | – | 0.46 | ||||||
| PPM1DPeds RMTL protein phosphatase, Mg2+/Mn2+ dependent 1D | 0.45 | – | 0.72 | ||||||
| ACVR1Peds RMTL activin A receptor type 1 | 0.45 | – | 0.72 | ||||||
| KDR kinase insert domain receptor | 0.44 | – | 0.57 | ||||||
| H3C2 H3 clustered histone 2 | 0.44 | – | 0.72 | ||||||
| ARID1A AT-rich interaction domain 1A | 0.43 | – | 0.56 | ||||||
| PIK3CB phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | 0.43 | – | 0.52 | ||||||
| METPeds RMTL MET proto-oncogene, receptor tyrosine kinase | 0.43 | – | 0.60 | ||||||
| JAK2Peds RMTL Janus kinase 2 | 0.43 | – | 0.57 | ||||||
| NRAS NRAS proto-oncogene, GTPase | 0.43 | – | 0.55 | ||||||
| MSH2 mutS homolog 2 | 0.43 | 0.56 | 0.53 | ||||||
| ATMPeds RMTL ATM serine/threonine kinase | 0.42 | 0.44 | 0.57 | ||||||
| PDCD1Peds RMTL programmed cell death 1 | 0.42 | – | – | ||||||
| LRP1B LDL receptor related protein 1B | 0.42 | – | 0.55 | ||||||
| ABL1Peds RMTL ABL proto-oncogene 1, non-receptor tyrosine kinase | 0.42 | – | 0.53 | ||||||
| FLT4 fms related receptor tyrosine kinase 4 | 0.42 | – | 0.46 | ||||||
| LZTR1 leucine zipper like post translational regulator 1 | 0.42 | – | 0.54 | ||||||
| ESR1 estrogen receptor 1 | 0.41 | – | 0.57 | ||||||
| WT1Peds RMTL WT1 transcription factor | 0.41 | – | 0.46 | ||||||
| ALKPeds RMTL ALK receptor tyrosine kinase | 0.41 | – | 0.57 | ||||||
| AR androgen receptor | 0.41 | – | 0.51 | ||||||
| RUNX1 RUNX family transcription factor 1 | 0.41 | – | 0.52 | ||||||
| FAT1 FAT atypical cadherin 1 | 0.41 | – | 0.62 | ||||||
| BCORPeds RMTL BCL6 corepressor | 0.40 | – | 0.48 | ||||||
| HIF1APeds RMTL hypoxia inducible factor 1 subunit alpha | 0.40 | – | 0.61 | ||||||
| DNMT3A DNA methyltransferase 3 alpha | 0.40 | – | 0.51 | ||||||
| CHEK2 checkpoint kinase 2 | 0.39 | – | 0.61 | ||||||
| TOP1 DNA topoisomerase I | 0.39 | – | 0.30 |
16 biomarkers in Glioblastoma have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Glioblastoma”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 47 accepted items exist; the first 47 were read. This is the published evidence, not treatment advice.
- MGMT Promoter Methylation level A
- EGFR VIII level B
- IDH1 R132 level B
- MGMT Underexpression level B
- PTEN Expression level B
- TERT Promoter Mutation level B
- EGFR Amplification level B
- EGFR Overexpression level B
- H3-3A K28M level B
- IDH2 R172 level B
- KIT EXPRESSION level B
- LRP1B Deletion level B